Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IQVIA HoldingsLTS:0JDM -1.57%85 Return-on-Tangible-Asset is 13.13% as of Mar. 2026, which is 16% below its 10-year median of 15.71. GuruFocus rates LTS:0JDM with a GF Score™ of 85/100 and a GF Value™ of $249.98 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, IQVIA Holdings ranks better than 88.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. IQVIA Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was $1,096 Mil. IQVIA Holdings's average total tangible assets for the quarter that ended in Mar. 2026 was $8,347 Mil. Therefore, IQVIA Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 13.13%.
The historical rank and industry rank for IQVIA Holdings's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0JDM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.08 Med: 15.71 Max: 30.02
Current: 16.9
During the past 13 years, IQVIA Holdings's highest Return-on-Tangible-Asset was 30.02%. The lowest was 2.08%. And the median was 15.71%.
LTS:0JDM's Return-on-Tangible-Asset is ranked better than 88.73% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs LTS:0JDM: 16.90
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
IQVIA Holdings Return-on-Tangible-Asset Related Terms
IQVIA Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for IQVIA Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JDM vs WAT, ILMN, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, IQVIA Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.13% mean?
IQVIA Holdings (LTS:0JDM) has a Return-on-Tangible-Asset of 13.13% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IQVIA Holdings and its competitors. This is 16% below median its historical median of 15.71. Over the past decade, IQVIA Holdings' Return-on-Tangible-Asset has ranged from 2.08 to 30.02. According to the industry distribution chart, IQVIA Holdings ranks #24 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 11.3%.
Is IQVIA Holdings' Return-on-Tangible-Asset too high?
IQVIA Holdings' current Return-on-Tangible-Asset of 13.13% is 16% below median its 10-year median of 15.71. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 30.02. Based on the distribution chart, IQVIA Holdings ranks #24 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IQVIA Holdings has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Return-on-Tangible-Asset compare to WAT and ILMN?
According to the Medical Diagnostics & Research industry distribution chart, IQVIA Holdings ranks #24 out of 213 companies for Return-on-Tangible-Asset. This places IQVIA Holdings in the top 11% of its industry — outperforming the majority of peers. Historically, IQVIA Holdings' own Return-on-Tangible-Asset has ranged from 2.08 to 30.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current Return-on-Tangible-Asset is 13.13%, which is 16% below median its own 10-year median of 15.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (LTS:0JDM) is currently considered Modestly Undervalued. The stock's GF Value™ is $249.98, compared to a current price of $206.23 — trading 17.5% below its estimated fair value. The current Return-on-Tangible-Asset is 13.13%, which is 16% below median its 10-year median of 15.71. IQVIA Holdings' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For IQVIA Holdings (LTS:0JDM), the current Return-on-Tangible-Asset is 13.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IQVIA Holdings (LTS:0JDM) Overvalued in 2026?
Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued.
The current stock price of $206.23 is trading 17.5% below its estimated GF Value™ of $249.98.
GuruFocus considers IQVIA Holdings to be Modestly Undervalued.
Key valuation signals for LTS:0JDM:
Return-on-Tangible-Asset: 13.13% (16% below median its 10-year median of 15.71)
GF Value™: $249.98 vs. price of $206.23 (17.5% below fair value)
No single metric tells the full story. See the LTS:0JDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
85GF Score
Get the complete analysis for LTS:0JDM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDM has been successfully added to your 
